ComPsych Corporation Announces 2024 Health at Work Award Winners
'At ComPsych, we understand that people-support drives business,' said ComPsych CEO Paul Posey. 'Mental health and well-being are not passing trends or a 'nice-to-haves.' These are critical investments in the very foundation of a thriving, sustainable business. We're thrilled to honor organizations that recognize this and have implemented programs and initiatives to foster a culture where the health and well-being of their teams is not an afterthought, but a key driver of organizational success.'
The 2024 ComPsych Health at Work Award winners are:
Specialty Awards – Mental Health Heroes: Honoring organizations for outstanding programs or initiatives aimed at supporting a positive mental health culture and reducing stigma.
Specialty Awards – Global Champion: Honoring organizations for the most dynamic and comprehensive global employment engagement.
Specialty Awards – Health Equity: Honoring organizations for outstanding programs that uniquely support underserved populations and improve health equity.
Specialty Awards – Innovative Integration: Honoring organizations for exemplary holistic programs, addressing the different dimensions of well-being including physical, financial, emotional, social and intellectual.
Specialty Awards – Power of Leadership: Honoring organizations for leadership that is committed to exemplifying the value of engaging in employee well-being initiatives.
For more information on ComPsych's Health at Work Awards, please visit here.
About ComPsych
ComPsych® Corporation is the world's largest provider of mental health services and GuidanceResources® for life. Fueled by a commitment to relentless innovation and a comprehensive approach to care, ComPsych provides services to more than 78,000 organizations and 163 million individuals across 200 countries. Our absence management services provide turnkey administration and expert guidance on federal FMLA, USERRA, jury/witness, company and state leaves as well as compliance with ADA, EEOC, and other regulations. Under our GuidanceResources® brand, our personalized and fully integrated programs include behavioral health and wellness journeys, which empower employees to lead healthier and more productive lives, while driving organizational excellence. Visit compsych.com to find out why 40% of the Fortune 500 choose ComPsych for their mental health and absence management needs.
Carolyn Linck
[email protected]
(312) 446-0339
SOURCE: ComPsych® Corporation
Copyright Business Wire 2025.
PUB: 04/09/2025 10:05 AM/DISC: 04/09/2025 10:05 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Yahoo
2 days ago
- Yahoo
Navamedic gains approval for Flexilev in OraFID packaging in Nordic countries
Navamedic has secured final approval for the Flexilev in OraFID tablet dispenser packaging material in the national languages of Norway, Sweden, and Denmark. OraFID is a patented, entirely mechanical medical device designed to deliver exact amounts of mini tablets to patients with a simple mechanism operated by a few twists of the hands. The company received the first approval of OraFID as the primary package for a pharmaceutical product in June 2025. The product licensor, Orion Corporation, has also received final confirmation for the Finnish market. Navamedic CEO Kathrine Gamborg Andreassen said: "We are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region." The Flexilev in OraFID dispenser is designed to provide precise and personalised treatment for patients with Parkinson's, particularly advantageous for medications with a narrow therapeutic window. Hyper-fractionation, which involves administering smaller, more frequent doses, is made possible through this approach. Following the acquisition of Sensidose in May 2023, Flexilev, a novel prescription treatment for Parkinson's disease, became part of Navamedic's product range. The launch of OraFID in the Nordic markets is anticipated this October. Navamedic entered into a licensing and supply agreement with Orion for the distribution of Flexilev, which includes OraFID, across Europe in June 2024. This agreement excludes Sweden, Norway, Denmark, and Iceland, where Navamedic retains the rights to market and sell the product. Orion has secured the exclusive rights to market, distribute, and sell Flexilev in 27 European countries, including the five largest markets: Germany, France, Italy, Spain, and the UK. Orion acts as the marketing authorisation holder within its designated territory and will carry all associated rights and obligations. "Navamedic gains approval for Flexilev in OraFID packaging in Nordic countries" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
2 days ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
